Factors affecting the feasibility of post-authorisation RCTs for conditionally authorised anticancer medicines: a multistakeholder perspective from a qualitative focus group study.
Saved in:
| Title: | Factors affecting the feasibility of post-authorisation RCTs for conditionally authorised anticancer medicines: a multistakeholder perspective from a qualitative focus group study. |
|---|---|
| Authors: | van Hattem CC; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands.; Medicines Evaluation Board, Utrecht, the Netherlands., de Jong AJ; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands., de Groot JS; Medicines Evaluation Board, Utrecht, the Netherlands., Hoekman J; Innovation Studies, Copernicus Institute of Sustainable Development, Utrecht University, Utrecht, the Netherlands., Broekman KE; Medicines Evaluation Board, Utrecht, the Netherlands.; Department of Medical Oncology, University Medical Centre Groningen, Groningen, the Netherlands., Sonke GS; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, University of Amsterdam, Amsterdam, the Netherlands., van Hennik PB; Medicines Evaluation Board, Utrecht, the Netherlands., Bloem LT; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands L.T.Bloem@uu.nl. |
| Source: | BMJ open [BMJ Open] 2024 Nov 09; Vol. 14 (11), pp. e084483. Date of Electronic Publication: 2024 Nov 09. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
